JP2024526202A - ナノ粒子を含有する核酸 - Google Patents

ナノ粒子を含有する核酸 Download PDF

Info

Publication number
JP2024526202A
JP2024526202A JP2023579371A JP2023579371A JP2024526202A JP 2024526202 A JP2024526202 A JP 2024526202A JP 2023579371 A JP2023579371 A JP 2023579371A JP 2023579371 A JP2023579371 A JP 2023579371A JP 2024526202 A JP2024526202 A JP 2024526202A
Authority
JP
Japan
Prior art keywords
nanoparticles
apolipoprotein
nucleic acid
nanoparticle
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526202A5 (cg-RX-API-DMAC7.html
Inventor
デア メール,ロイ ヴァン
ジェイ.エム. マルダー,ウィレム
クルザ,エヴェリナ
ホフストラート,スティン
アンベルゲン,トム
コルネリス ズウォルスマン,ロビー
マリー ヤンセン,ヘンリクス
ミシェル フランセン,ピーター
Original Assignee
バイオ-トリップ ベーフェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオ-トリップ ベーフェー filed Critical バイオ-トリップ ベーフェー
Publication of JP2024526202A publication Critical patent/JP2024526202A/ja
Publication of JP2024526202A5 publication Critical patent/JP2024526202A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023579371A 2021-06-22 2022-06-22 ナノ粒子を含有する核酸 Pending JP2024526202A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21180786 2021-06-22
EP21180786.2 2021-06-22
PCT/EP2022/067073 WO2022268913A1 (en) 2021-06-22 2022-06-22 Nucleic acid containing nanoparticles

Publications (2)

Publication Number Publication Date
JP2024526202A true JP2024526202A (ja) 2024-07-17
JP2024526202A5 JP2024526202A5 (cg-RX-API-DMAC7.html) 2025-06-27

Family

ID=76553579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579371A Pending JP2024526202A (ja) 2021-06-22 2022-06-22 ナノ粒子を含有する核酸

Country Status (10)

Country Link
US (1) US20240216291A1 (cg-RX-API-DMAC7.html)
EP (1) EP4358936A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024526202A (cg-RX-API-DMAC7.html)
KR (1) KR20240025611A (cg-RX-API-DMAC7.html)
CN (1) CN117545467A (cg-RX-API-DMAC7.html)
AU (1) AU2022296780A1 (cg-RX-API-DMAC7.html)
CA (1) CA3222851A1 (cg-RX-API-DMAC7.html)
IL (1) IL309578A (cg-RX-API-DMAC7.html)
MX (1) MX2023014901A (cg-RX-API-DMAC7.html)
WO (1) WO2022268913A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2023227682A1 (en) 2022-05-24 2023-11-30 Bio-Trip B.V. Modified apolipoproteins with a targeting body for lipid nanoparticles
WO2024200824A1 (en) 2023-03-29 2024-10-03 Bio-Trip B.V. Apolipoprotein lipid nanoparticle
CN117567541A (zh) * 2023-11-16 2024-02-20 中国科学技术大学 甾类阳离子脂质化合物、脂质纳米颗粒及其制备方法与应用
WO2025190968A1 (en) 2024-03-11 2025-09-18 Bio-Trip B.V. Apolipoprotein lipid nanoparticle
WO2026029597A1 (ko) * 2024-07-31 2026-02-05 주식회사 메디치바이오 신규한 스테롤 지질 또는 이의 유도체를 함유하는 지질 나노입자 조성물
GB202412885D0 (en) * 2024-09-03 2024-10-16 Imperial College Innovations Ltd Three component lipid nanoparticles
WO2026107609A1 (en) * 2024-11-25 2026-05-28 Nanovation Therapeutics Inc. Lipid nanoparticles having non-polar lipids for extrahepatic nucleic acid delivery
CN120607455B (zh) * 2025-08-06 2025-10-21 中国科学院长春应用化学研究所 可电离脂质、其立体异构体或药学上可接受的盐、制备方法和应用
CN121059567A (zh) * 2025-11-07 2025-12-05 中国医学科学院输血研究所 一种脂质纳米颗粒及其应用、药物递送载体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520082A (ja) * 2009-03-12 2012-09-06 アルナイラム ファーマシューティカルズ, インコーポレイテッド 脂質製剤組成物およびEg5遺伝子とVEGF遺伝子の発現を阻害する方法
JP2021504446A (ja) * 2017-11-21 2021-02-15 アイカーン スクール オブ メディスン アット マウント サイナイ 治療用ナノ生物学的組成物による訓練免疫の促進

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4995423B2 (ja) * 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
EP2217221B1 (en) * 2007-10-17 2018-06-27 Korea Advanced Institute of Science and Technology Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
US8268796B2 (en) * 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
EP2391343B1 (en) * 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
WO2011044545A2 (en) * 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
GB201800370D0 (en) * 2018-01-10 2018-02-21 Ucl Business Plc Anionic nanocomplexes for nucleic acid delivery
EP3947646A1 (en) * 2019-04-05 2022-02-09 Precision BioSciences, Inc. Methods of preparing populations of genetically-modified immune cells
SG11202111066UA (en) * 2019-04-26 2021-11-29 Univ Northwestern High density lipoprotein nanoparticles and rna templated lipoprotein particles for ocular therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520082A (ja) * 2009-03-12 2012-09-06 アルナイラム ファーマシューティカルズ, インコーポレイテッド 脂質製剤組成物およびEg5遺伝子とVEGF遺伝子の発現を阻害する方法
JP2021504446A (ja) * 2017-11-21 2021-02-15 アイカーン スクール オブ メディスン アット マウント サイナイ 治療用ナノ生物学的組成物による訓練免疫の促進

Also Published As

Publication number Publication date
US20240216291A1 (en) 2024-07-04
AU2022296780A9 (en) 2023-12-14
IL309578A (en) 2024-02-01
EP4358936A1 (en) 2024-05-01
AU2022296780A1 (en) 2023-12-07
CA3222851A1 (en) 2022-12-29
WO2022268913A1 (en) 2022-12-29
KR20240025611A (ko) 2024-02-27
CN117545467A (zh) 2024-02-09
MX2023014901A (es) 2024-04-29

Similar Documents

Publication Publication Date Title
US20240216291A1 (en) Nucleic Acid Containing Nanoparticles
ES2561812T3 (es) Composición para inhibir la expresión de un gen diana
JP2017500865A (ja) レプチンmRNAの組成物および製剤
JP2023531511A (ja) 半減期が延長されたmRNA治療薬を含むLNP組成物
US20090011003A1 (en) Composition for Suppressing Expression of Target Gene
JP2023533864A (ja) 式-nh-cx-aまたは-nh-cx-nh-aの少なくとも1つの末端ラジカルを含む脂質化合物、それらを含有する組成物およびそれらの使用
US20250325491A1 (en) Polyvalent molecule based lipid nanoparticles for nucleic acid delivery
JP5407862B2 (ja) siRNAおよび脂質性4,5−二置換2−デオキシストレプタミン環アミノグリコシド誘導体を含む組成物ならびにその用途
KR20230150852A (ko) 게놈 편집 구형 핵산 (sna) 개발 전략
CN110506047B (zh) 核酸导入用脂质衍生物
TW201625310A (zh) CKAP5基因表現抑制RNAi醫藥組合物
WO2023159197A1 (en) Mrnas encoding checkpoint cancer vaccines and uses thereof
JP2023534279A (ja) 切断可能な脂質化合物、それを含む組成物、およびその使用
WO2023048572A1 (en) Targeted lipid nanoparticle formulations
TW202315601A (zh) ApoE胜肽之使用方法
WO2022147304A1 (en) Compositions and methods for treating metabolic disorders
JP2018016642A (ja) 脂質粒子の製造法および脂質粒子を有する核酸送達キャリア
EP4667475A1 (en) Ph-responsive phospholipid
WO2025063214A1 (ja) 核酸を内封したリガンド修飾脂質ナノ粒子の製造方法
WO2025245188A2 (en) Methods of treating liver steatosis and non-alcoholic fatty liver disease
WO2024118592A2 (en) Methods of using extracellular vesicle-aso targeting stat6
EP4547259A2 (en) Methods of using extracellular vesicle-aso targeting stat6
WO2011007795A1 (ja) 標的遺伝子の発現を抑制する組成物
US20150247148A1 (en) Composition for suppressing expression of target gene

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260724